



Corporate Press Release

23 August 2010

NORGINE PARTNERS WITH MODI-MUNDIPHARMA FOR MOVICOL® AND MOVIPREP® IN THE INDIAN SUB-CONTINENT

Norgine, the leading European specialty pharmaceutical company, has today announced that it has appointed Modi-Mundipharma as its regional partner for MOVICOL and MOVIPREP in India, Bangladesh, Nepal, Bhutan and Sri Lanka.

MOVIPREP is a new generation product developed by Norgine for bowel cleansing prior to colonoscopy and other situations where a clean bowel is required. MOVICOL is a treatment for chronic constipation and faecal impaction and is the leading prescription laxative brand in Europe.

Commenting on the agreement Umesh Kumar Modi, Chairman and President of Modi-Mundipharma, said "Collaboration with Norgine will enable us to strengthen our presence in the gastroenterology segment with their world renowned products. The international image and marketing expertise of Norgine will propel us to new heights of success. Norgine is going to be a strategic fit in our product portfolio. Our endeavour has always been towards bringing world class medicines to India"

Commenting on the agreement Peter Stein, Norgine's CEO, said "We are delighted to be working with Modi-Mundipharma on what will be our first products to be launched in the Indian market. They have a well established and fast growing business in the Indian sub-continent and this, coupled with their broad partnering experience, makes them the ideal regional partner for Norgine"

About Norgine

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2009, Norgine's net product sales were €253 million, the 23rd year of double-digit growth at constant exchange rates. The company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in various markets in its key therapeutic areas e.g. MOVICOL for the treatment of constipation and faecal impaction, MOVIPREP a new generation of bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France. www.norgine.com

Norgine Contact

Julie Hornby Winfield
Global Corporate Communications Manager
+44 (0) 1895 826600
jhornbywinfield@norgine.com

About Modi-Mundipharma

Modi-Mundipharma is a 50:50 joint venture between the privately held Mundipharma Group (known as Purdue Pharma in the USA, Napp Laboratories in the UK and Mundipharma in Europe) and Mr. Umesh K. Modi of the Modi Group of Industries, a leading business conglomerate in India. Mundipharma globally is a US \$4.2 Bn enterprise

Modi-Mundipharma (& its associates companies) market Betadine range and foster all other in licensed global products along with its indigenous formulations. Modi-Mundipharma gained a strong hold in the Indian market with Mundipharma's Continus technology, a differentiated and unique NDDS endorsed by medical practitioners' world over across 70 countries.

Driven by the desire to maintain leadership through innovation, Modi-Mundipharma has successfully carved out a unique strategy of in-licensing innovative products with international alliances with reputed global companies for marketing their products in India. This has enabled Modi-Mundipharma to leverage their marketing edge and make a successful foray across therapeutic segments like Gastroenterology, Dermatology, Gynaecology and Oral Care through alliances with Merz Pharma of Germany (Hepamerz , Contractubex, Mederma), Tillots of Switzerland (Asacol), IBSA of Switzerland (Gonadotrophins), Orion Pharma of Finland (Divigel and other HRT products), LEO Pharma of Denmark (DAIVONEX® , DAIVOBET®) for their dermatology portfolio and Pierre Fabre of France for their Oral care products , Sigma tau of Italy for their flagship

brand Carnitor (L-Carnitine), Thornton & Ross of UK for their head lice product – Hedrin.

Among its recent ventures, Modi-Mundipharma last year has entered into joint venture collaboration with Omega Pharma, Belgium. Omega Pharma is among the top 15 OTC Company worldwide and has operations in almost 40 countries.

To meet our growing business demands for both domestic and world markets, Modi-Mundipharma has five world class manufacturing plants for various formulations. Among these plants T.C. Healthcare is the recently established UK-MHRA approved Tablet Production Plant exporting to European countries.

Modi-Mundipharma's consistent endeavour has brought the group among the league of elite companies in India. In the pharma segment Modi-Mundipharma is the 7th largest multinational company in India and is ahead of Astra Zeneca, Janssen Cilag & Solvay pharma

Modi-Mundipharma group (pharma & cosmetics) one of the largest privately held organization in India has one of the largest sales forces with more than 4,000 sales employees.